Data suggest that activation of GIP-R decreases inflammation in adipose tissue and cytokines levels (such as IL-6) and promotes the rise of serum adiponectin levels, a cytokine with anti-inflammatory effects and beneficial effects on diabetic nephropathy, which can explain potential beneficial effects on kidneys (even if GIP-R are not present) (47). Here, GIPR is linked to diabetic kidney disease.